Aligos Therapeutics Inc at Jefferies Healthcare Conference Transcript
All right. Thank you. Good morning, everyone, and welcome to the morning session of the Jefferies Healthcare Conference. Really happy to introduce from Aligos Therapeutics, the CEO and Co-Founder -- Chairman, CEO and Co-Founder, Lawrence Blatt. He's going to give a nice update on Aligos Therapeutics, a pipeline advancing. And without further ado, won't you come on up, Lawrence?
Thanks, Michael, and thanks for inviting us to the conference. So we're going to be making some forward-looking statements today. So this is our disclosure statement.
So we're a company, Aligos Therapeutics, that has several early-stage clinical development programs. Our lead program right now is ALG-009, and that's a small molecule beta thyroid agonist working in the NASH space. I'm going to go into a lot of detail on that data.
In addition to that, we have collaboration with Merck for oligonucleotides targeting NASH targets. That program, the targets are confidential, and Merck
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |